期刊论文Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA®)复制

DOI:复制

文献链接:复制

其他信息:

S Tokunaga, Y Endo, T Kawata
Nihon Yakurigaku Zasshi. Folia …, 2019
europepmc.org
Calcimimetics allosterically activate the calcium receptor (CaR) and inhibit the secretion of parathyroid hormone (PTH). Cinacalcet hydrochloride (cinacalcet) has been approved as the first calcimimetic drug for the treatment of secondary hyperparathyroidism (SHPT) in patients with hemodialysis. Cinacalcet improved the achievement of target serum PTH and Ca levels and helped drastically reduce the number of parathyroidectomies. However, cinacalcet has side effects involving the gastrointestinal tract, such as nausea and vomiting …